AstraZeneca has reported data from the P-III (ADRIATIC) clinical evaluation of Imfinzi (1500mg, Q4W) alone and in addition with Imjudo (75mg, Q4W) vs PBO for treating limited-stage small cell lung cancer patients (n=730) who did not progress post concurrent chemoradiation therapy
The data depicted improved dual-1EPs of OS and PFS with a consistent safety profile as compared to the previous studies and there were no new safety outcomes observed with Imfinzi. Results will be highlighted at the upcoming medical conferences
Another cohort of the trial investigating the effectiveness of Imfinzi in combination with Imjudo as a 2EP remains blinded and will proceed through the next anticipated analysis
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Highlights Results from the P-III (DUO-E) Study Evaluating Imfinzi for the Treatment of Endometrial Cancer at SGO 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
